Perhaps nothing triggers frustration and hope in patients like prescription drugs.
Consider the hepatitis C drug Sovaldi, infamous for its $84,000 retail price tag for a 12-week course.
Despite the price, the drug embodies significant hope. It, and other recently approved hepatitis C medications, have vastly improved treatment of the disease.
Sovaldi’s potential was confirmed during clinical trials when it was tested on humans as part of the drug approval process. Many hepatitis B patients probably wish they could have participated.
Read Full Article »